42 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Apoetm1Unc/Apoetm1Unc Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129P2/OlaHsd * 129S6/SvEvTac	decreased macrophage cell number	J:110044
	decreased susceptibility to atherosclerosis	J:110044
	vascular smooth muscle hypoplasia	J:110044
Col4a3tm1Jhm/Col4a3tm1Jhm Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ	abnormal renal glomerulus basement membrane morphology	J:63137
	glomerulonephritis	J:63137
	increased renal glomerulus basement membrane thickness	J:63137
Dmdmdx/Dmdmdx Mmp9tm1Tvu/Mmp9+ B10.Cg-Mmp9tm1Tvu Dmdmdx	abnormal muscle morphology	J:150030
	abnormal muscle physiology	J:150030
	decreased macrophage cell number	J:150030
	enhanced skeletal muscle regeneration	J:150030
Dmdmdx/Dmdmdx Mmp9tm1Tvu/Mmp9tm1Tvu B10.Cg-Mmp9tm1Tvu Dmdmdx	abnormal muscle morphology	J:150030
	decreased macrophage cell number	J:150030
	enhanced skeletal muscle regeneration	J:150030
Hspg2tm1Ref/Hspg2tm1Ref Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ	abnormal long bone metaphysis morphology	J:84739
	disorganized long bone epiphyseal plate	J:84739
	increased diameter of humerus	J:84739
	short humerus	J:84739
Mmp2tm1Ito/Mmp2tm1Ito Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129P2/OlaHsd * 129S6/SvEvTac	decreased susceptibility to induced choroidal neovascularization	J:86805
Mmp8tm1Otin/Mmp8tm1Otin Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6	normal immune system phenotype	J:113463
Mmp9tm1Tvu/Mmp9tm1Tvu Rag2tm1Fwa/Rag2tm1Fwa B6.129S-Rag2tm1Fwa Mmp9tm1Tvu	decreased tumor incidence	J:105098
Mmp9tm1Tvu/Mmp9tm1Tvu Rag2tm1Fwa/Rag2tm1Fwa involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * FVB/N	abnormal tumor morphology	J:140033
	decreased metastatic potential	J:140033
	decreased tumor growth/size	J:140033
Mmp9tm1Tvu/Mmp9tm1Tvu Sftpdtm1Jhf/Sftpdtm1Jhf involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * FVB/N	overexpanded pulmonary alveolus	J:121212
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(KRT14-HPV16)wt1Dh/0 involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N	abnormal epidermal layer morphology	J:65699
	decreased keratinocyte proliferation	J:65699
	decreased tumor incidence	J:65699
	increased skin squamous cell carcinoma incidence	J:65699
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0 involves: 129S6/SvEvTac * C57BL/6 * FVB/N	abnormal tumor morphology	J:140033
	decreased metastatic potential	J:140033
	decreased tumor growth/size	J:140033
	increased mammary gland tumor incidence	J:140033
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0 involves: 129S6/SvEvTac * FVB/N	increased mammary gland tumor incidence	J:140033
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(SOD1*G93A)1Gur/0 involves: 129S6/SvEvTac * C57BL/6 * CD-1 * SJL	decreased tumor necrosis factor secretion	J:141587
	normal mortality/aging	J:141587
	normal nervous system phenotype	J:141587
Mmp9tm1Tvu/Mmp9tm1Tvu Timp1tm1Pds/Timp1tm1Pds involves: 129S4/SvJae * 129S6/SvEvTac	normal immune system phenotype	J:94836
Mmp12tm1Sds/Mmp12tm1Sds Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * 129X1/SvJ	abnormal myelination	J:105765
	decreased oligodendrocyte number	J:105765
	decreased susceptibility to induced aneurysm formation	J:62760
Mmp13tm1.1Werb/Mmp13tm1.1Werb Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S2/SvPas * 129S6/SvEvTac	abnormal bone marrow cavity morphology	J:94460
	abnormal long bone epiphyseal ossification zone morphology	J:94460
	abnormal long bone hypertrophic chondrocyte zone	J:94460
	abnormal trabecular bone morphology	J:94460
	decreased body size	J:94460
	delayed bone ossification	J:94460
	increased width of hypertrophic chondrocyte zone	J:94460
Mmp13tm1Jdar/Mmp13tm1Jdar Mmp9tm1Tvu/Mmp9tm1Tvu involves: 129S6/SvEvTac * C57BL/6J * FVB/N	abnormal epiphyseal plate morphology	J:150790
	decreased angiogenesis	J:150790
	decreased cell proliferation	J:150790
	delayed wound healing	J:150790
	postnatal growth retardation	J:150790